The Emerging Field of Race-Based Genetic Research: Can We Trust It?

DSpace/Manakin Repository

The Emerging Field of Race-Based Genetic Research: Can We Trust It?

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Gupta, Alpana en_US
dc.date.accessioned 2012-06-07T20:42:28Z
dc.date.issued 2006 en_US
dc.identifier.citation The Emerging Field of Race-Based Genetic Research: Can We Trust It? (2006 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852195
dc.description.abstract In June of 2005, the Food and Drug Administration approved a heart disease drug named BiDil exclusively for African Americans, provoking a fiery debate among medical researchers, sociologists, and legal scholars. On the one hand, some researchers have expressed concern that race-based drugs such as BiDil promote the notion that race carries a biological component. They emphasize that the use of such drugs will lead to harms against minorities, such as increased discrimination and the worsening of racial health disparities. Proponents of race-based drugs, on the other hand, argue that race is merely a temporary proxy for underlying genetic patterns, to be replaced by more precise indicators of drug efficacy in the future as technology advances. This paper explores the relationship between race and genetics, the significance this relationship may have in the field of medicine, and the long-term consequences race-based research may hold for minorities. This paper begins by describing the context surrounding the development of BiDil to illuminate why companies are beginning to pursue race-based research during this particular decade. The second part of the paper discusses the concept of race. It begins by outlining the way the law has historically understood the concept of race and concludes with a lengthy overview of genetic studies of racial disparities in terms of both disease susceptibility and drug response. Part III of the paper explores the dangers opponents of race-based research claim such research will have, while the final part of the paper proposes ways FDA may be able to curb such harms. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject genetics en
dc.title The Emerging Field of Race-Based Genetic Research: Can We Trust It? en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T20:42:28Z

Files in this item

Files Size Format View
Gupta06.pdf 621bytes PDF View/Open
Gupta06.rtf 346.1Kb RTF file View/Open
Gupta06.html 199.0Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters